Study
| Randomized, controlled, phase 3 trial (TRITON-3) |
| Metastatic, castration-resistant prostate cancer with a BRCA1, BRCA2, or ATM alteration and who had disease progression after treatment with a second-generation androgen-receptor pathway inhibitor (ARPI) |
| Rucaparib (n=270) vs. SOC (n=135) |
Efficacy
| BRCA1/2 mutant subgroup |
| mrPFS: 11.2 vs. 6.4 mos, p<0.001 |
| İTT group |
| mrPFS: 10.2 vs. 6.4 mos, p=<0.001 |
Safety
| Any grade: fatigue (61.% vs. 63%), nausea (50% vs 19%), anemia (47% vs 18%), diarrhea (31% vs. 28%) |
| Grade≥3 AEs: anemia (24% vs. 1%), fatigue (7% vs. 9%). |
N Engl J Med 2023; 388:719-732
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
http://doi.org/10.1056/NEJMoa2214676
Reviewed by Elvin Chalabiyev, MD on Apr 14, 2023
